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Abstract
Background: At least a third of patients with a colorectal carcinoma who are candidate for surgery, are anaemic
preoperatively. Preoperative anaemia is associated with increased morbidity and mortality. In general practice, little
attention is paid to these anaemic patients. Some will have oral iron prescribed others not. The waiting period prior
to elective colorectal surgery could be used to optimize a patients’ physiological status. The aim of this study is to
determine the efficacy of preoperative intravenous iron supplementation in comparison with the standard
preoperative oral supplementation in anaemic patients with colorectal cancer.
Methods/Design: In this multicentre randomized controlled trial, patients with an M0-staged colorectal carcinoma
who are scheduled for curative resection and with a proven iron deficiency anaemia are eligible for inclusion. Main
exclusion criteria are palliative surgery, metastatic disease, neoadjuvant chemoradiotherapy (5 × 5 Gy = no exclusion)
and the use of Recombinant Human Erythropoietin within three months before inclusion or a blood transfusion
within a month before inclusion. Primary endpoint is the percentage of patients that achieve normalisation of the
haemoglobin level between the start of the treatment and the day of admission for surgery. This study is a superiority
trial, hypothesizing a greater proportion of patients achieving the primary endpoint in favour of iron infusion compared
to oral supplementation. A total of 198 patients will be randomized to either ferric(III)carboxymaltose infusion in the
intervention arm or ferrofumarate in the control arm. This study will be performed in ten centres nationwide and one
centre in Ireland.
Discussion: This is the first randomized controlled trial to determine the efficacy of preoperative iron supplementation
in exclusively anaemic patients with a colorectal carcinoma. Our trial hypotheses a more profound haemoglobin
increase with intravenous iron which may contribute to a superior optimisation of the patient’s condition and
possibly a decrease in postoperative morbidity.
Trial registration: ClincalTrials.gov: NCT02243735.
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Background
Colorectal carcinoma has a peak incidence in the seventh
decade of life and patients often presents with comorbid
iron deficiency anaemia. At least a third of patients with a
colorectal carcinoma who undergo surgery, are anaemic
preoperatively [1].
Anaemia in patients with colorectal carcinoma is partly
caused by gastro-intestinal (GI) blood loss and is partly
cancer-related. Cancer related anaemia is multifactorial
and is caused by impaired iron absorption, nutritional
deficiency and anaemia of chronic disease, which is a
cytokine-mediated disorder. These effects cause functional
iron deficiency, which is characterized by insufficient
available iron at the site of erythroblast production (iron
restricted erythropoiesis) with adequate iron stores [2]. In
addition, iron is an essential component of a large number
of human metabolic enzymes, including ribonucleotide re-
ductase and NADH dehydrogenase [3, 4]. Therefore iron
deficiency even without concomitant anaemia is associ-
ated with fatigue [5, 6], impaired physical performance
and cognitive function [7–9].
Currently there are three options in the treatment of
anaemia: blood transfusion, erythropoietin stimulating
agents (ESA) and iron supplementation. Blood transfusion
and ESA are effective modalities in increasing haemoglo-
bin (HB) levels, however both modalities should be given
with caution in oncologic patients as they are associated
with an increased risk of cancer recurrence [10, 11] and
ESA is even associated with an 17 % increase in overall
mortality in oncologic patients [12].
With the application of laparoscopic surgery, blood
loss is limited and blood transfusions are rarely neces-
sary. In the LAFA study including 50 % open and 50 %
laparoscopic segmental colectomies the blood transfu-
sion rate was only 4 %[1]. This decreasing rate of blood
transfusion could be a reason for the moderate attention
for the treatment of light to moderate anaemia in the
preoperative setting. However it has been shown that
preoperative anaemia, even to a mild degree, is inde-
pendently associated with an increased risk of morbidity
and 30-day mortality [12, 13].
There is no standard of care in the treatment of light
to moderate anaemia in the preoperative setting; some
will have oral iron prescribed others not. A more pro-
found treatment of iron deficiency anaemia could play a
crucial role in optimizing patient’s condition prior to
surgery [5]. Even tumour response on chemotherapy, as
suggested by Lindsey [14], could be negatively influenced
by low HB levels [15, 16]. In the Netherlands, average
waiting time before surgery in case of a colorectal car-
cinoma is two to three weeks. This period could be used
more effective in the optimisation of patients towards
surgery. Studies on iron supplementation (both oral and
intravenous) prior to orthopaedic [17] and gynaecologic
surgery [18] showed that iron supplementation is effect-
ive in treating anaemia, reducing blood transfusions and
also reducing length of stay [19].
However, in patients with colorectal carcinoma and con-
comitant anaemia current evidence on the role of iron
supplementation seems inconclusive. This is due to meth-
odological short comings of the studies, with small study
populations [20, 21], heterogeneity in iron preparations
supplied, the lack of data on surgical outcomes and most
importantly due to inclusion of both anaemic and non-
anaemic patients [20, 22]. All of the above underlines the
need for a new trial on the efficacy of pre-operative iron
therapy in treatment of anaemia in patients with a colo-
rectal carcinoma and its effect on outcomes after surgery.
Methods/design
The aim of this multicentre trial is to investigate which
route of iron supplementation is superior in the treatment
of iron deficiency anaemia in patients with colorectal car-
cinoma. By enhancing the preoperative condition of the
patient, this trial aims to optimize postoperative outcome
in anaemic patients. It is our hypothesis that a more
profound approach of anaemia with intravenous iron
will lead to a higher percentage of patients with
normalization of Hb-level (>12 g/dl (7.5 mmol/l) for
women and > 13 g/dl (8 mmol/l) for men) undergoing
surgery, which potentially reduces morbidity, length of
hospital stay, improves quality of life, decreases fatigue
and could be more cost effective compared to current
practice with oral substitution of iron.
In addition, an economic evaluation of intravenous iron
versus oral iron will be performed. The evaluation will be
performed from a societal perspective as (i) a cost-
effectiveness analysis with the costs per responder to iron
supplementation therapy as primary outcome and (ii) a
cost-utility analysis with the costs per quality adjusted life-
year (QALY) as primary outcome. The cost effectiveness
analysis closely relates to clinical efficacy measure and al-
lows for setting priorities in treatment of anaemia in colo-
rectal cancer patients. The cost-utility analysis allows for a
comparison of the societal impact of intravenous iron sup-
plementation on post-operative recovery, such as im-
proved health utility, shorter length of stay and earlier
return to daily activities.
The primary aim of the FIT trial
1) To compare the percentage of patients with
normalization of Hb-level (>12 g/dl (7.5 mmol/l) for
women and > 13 g/dl (8 mmol/l) for men) after
intravenous versus oral iron therapy in patients
undergoing curative surgery for colorectal
carcinoma.
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Secondary aims of the FIT trial are:
2) To analyse the effect of preoperative iron therapy
(intravenous versus oral) on postoperative morbidity,
length of stay, amount of blood transfusions needed
and quality of life and fatigue scores.
3) To determine the cost effectiveness of preoperative
intravenous iron substitution in comparison with
oral substitution.
Study design
The study is designed as a multicentre randomized clin-
ical trial comparing ferric(III)carboxymaltose infusion
with oral supplementation of ferrofumarate in the treat-
ment of preoperative anaemia in colorectal cancer pa-
tients. Patients with a proven iron deficiency anaemia
who undergo segmental colonic resection or (low) anter-
ior resection because of M0-stage colorectal carcinoma
are eligible for inclusion. Patients undergoing local exci-
sion of a rectal carcinoma (TEM/EMR/ESR) will not be
included. In Fig. 1 you can find the flowchart of the FIT-
trial.
When a patient has got a proven iron deficiency an-
aemia and the patient does not meet the criteria for exclu-
sion, he/she will be included in the trial. Written informed
consent will be obtained from each patient. The patients’
Figure 1 Flowchart of FIT-trial
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albumin and C-reactive protein (CRP) levels are used to
derive a Glasgow Prognostic Score (GPS) which can be
used as a predictor of post-operative outcome.
Patients will be computer randomized in random blocks
of sizes 2 or 4 for either intravenous- or oral iron.
Randomization will be stratified for age, colon or rectal
carcinoma, open or laparoscopic operation and baseline
Hb (8–10 g/dl vs 10–13 g/dl).
Apart from routine 5 year oncological follow-up, pa-
tients will be followed more intensively until 6 months
after surgery as part of this trial. Hb, transferrin satur-
ation (TSAT), ferritin, Hematocrit and CRP levels are
measured at postoperative day 1, day 7, at 4, 8 and
12 weeks to monitor the anaemia.The follow-up sched-
ule is detailed in Fig. 2.
Study procedures
Surgical procedures include all laparoscopic and open
segmental resections. Patients randomized to intraven-
ous iron will receive ferric(III)carboxymaltose dosed ac-
cording to Summary of Product Characteristics (SPC)
depending on body weight and Hb-level and it will be
administered in one or two infusions with one week in
between, prior to the operation. (also see Table 1). The
maximum dose administered to the patient may not
exceed 15 mg/kg and a maximum of 1000 mg may be
administered per week. When the patient has a weight
of lower than 35 kg, a dose of 500 mg will be given. Pa-
tients randomized to intravenous iron will receive iron
infusion on the short stay/colon care unit. Ferric(III) car-
boxymaltose has to be infused in a period of 15 min.
Patients randomized to standard care with ferrofumarate
will receive three tablets of 200 mg daily from random-
isation until day before surgery. This dose is conform
national farmacotherapeutic protocol [23]. When pa-
tients remain anaemic postoperatively, they will be
supplied with iron according to the allocated study arm.
Study population
The patient population consists of patients with M0-
stage colorectal carcinoma and concomitant iron defi-
ciency anaemia (Hb <7,5 mmol/l (12 g/dl) for women
and Hb < 8 mmol/l (13 g/dl) for men and TSAT < 20 %)
who will undergo a laparoscopic/open segmental colonic
resection or (low) anterior resection. Additionally the
patient should be 18 years of age or older and informed
consent must be obtained. Exclusion criteria are: palliative
surgery/metastasized disease, blood transfusion within
one month before screening, serum ferritin above 800 μg/
L, pregnancy, contraindication to use ferric(III)carboxy-
maltose or ferrofumarate, ASA classification higher than
3, the use of erythropoietin stimulating agents within
three months before screening, chronic kidney disease
(Glomerular filtration rate (GFR) <30 ml/min/m), myelo-
dysplastic syndrome, elevated liver enzymens (more than
three times normal value), hereditary hemochromatosis,
thalassemia, haemolytic anaemia/ chronic haemolysis.
Outcome parameters
Our primary endpoint is the percentage of patients with
normalization of Hb-level from start treatment until sur-
gery (Hb >12 g/dl (7.5 mmol/L) for women and Hb >13
Figure 2 Study follow-up
Table 1 Determining the cumulative dose of
ferric(III)carboxymaltose






1500 mg 2000 mg
>6.2 mmol/L
(10 g/dl)
1000 mg 1500 mg
N.B: The maximum dose administered per week is 1000 mg. The maximum
dose administered per patient may not exceed 15 mg/kg. Therefore, for
patients with a weight under 67 Kg, all calculated doses should be given in
two infusions (as 1000/15 = 66.7)
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g/dl (8.0 mmol/L) for men). Our secondary endpoints are
morbidity, assessed with the Comprehensive Complication
index, amount of blood transfusions needed, length of
stay, absolute change in HB from baseline prior to surgery
and postoperatively, time needed to achieve normalization
of Hb-level, change in baseline of other iron/haemato-
logical parameters (TSAT, ferritin, CRP), health-related
quality of life and fatigue scores (EQ-5D, EORTC-C30,
EORTC -CR29 iMCQ, BFI & iPCQ), relation between an-
aemia and Glasgow Prognostic Score (derived from CRP
and Albumin) and cost-effectiveness of intravenous iron
treatment compared to oral. Blood samples to assess Hb-
and iron values will be taken at baseline, at admission,
postoperative day 1, 7 and after 1-,2- and 3 months.
Sample size calculation
The principal analysis will be an intention-to-treat com-
parison of the proportions of patients with iron defi-
ciency anaemia between the two study groups. The trial
is designed as a superiority trial, hypothesizing a greater
percentage of patients achieving normalization of Hb-
level (called ‘responder’) in favour of infusion of ferri-
c(III)carboxymaltose compared to oral iron suppletion.
Our power calculation is based on the study of Seid et al.
[24], which compared ferric(III)carboxymaltose with oral
ferrous sulphate in a population of post-partum women
with an iron deficiency anaemia. The proportion achieving
a normalization of Hb after two weeks of treatment was
55 % in the intravenous iron group and 35 % in the oral
iron group. We expect that the efficacy of the iron therapy
is lower in patients with a colorectal carcinoma. There-
fore, the expected percentage of patients who achieve
normalization of Hb-level (Hb >7.5 mmol/l (12 g/dl) for
women and Hb >8.0 mmol/l (13 g/dl) for men) is 45 % in
the intravenous iron group and 25 % in the oral iron
group. Based on these proportions, a sample size of 89 pa-
tients per group is needed for a Chi square test to achieve
80 % power at a two sided alpha of 0.05. With an esti-
mated loss to follow up of 10 %, a sample size of 198 is
calculated. We used nQuery advisor version 7.0 to calcu-
late the sample size.
Data-analysis
The intention-to-treat population will include all patients
who give their informed consent, for whom there is con-
firmation of successful allocation of a randomization
number, and who received at least one dose of the study
medication. Statistical analyses will be performed using
SPSS software for Windows version 19.
The primary endpoint, the percentage of patients with
a normalised Hb-level at admission will be compared be-
tween the two study groups on a intention to treat basis.
Using a two-sided Chi-square test at a significance level
of 0.05. All data will be collected in an electronic
database. The outcome parameters will be analysed with
appropriate statistical tests by a statistician blinded for
the treatment allocation using the statistical program
SPSS software for Windows version 19.
Appropriate summary descriptive statistics will be de-
termined for all secondary endpoints at each visit using
raw scores. To assess morbidity the continuous scale of
the Comprehensive Complication Index [25] and the
categorical Clavien-Dindo classification will be used, for
which appropriate statistical tests will be undertaken
(the Mann Whitney U test, in case of non-normal distri-
bution, and the Chi squared test respectively). For con-
tinuous secondary endpoints, either analysis of variance
or analysis of covariance models will be used and where
necessary, the repeated measures procedure will be
implemented.
Quality of life data (e.g. EORTC-C30, EORTC-CR29
and EQ-5D) will be graphically represented across all
time points and analysed using a repeated measures ana-
lysis of variance. All tests based on proportions will be
analysed using a logistic regression model with treatment
as a factor and, where appropriate, other specified covari-
ates to include baseline score. Time-to-event will be ana-
lysed with use of Kaplan-Meier Survival analysis and
compared using the log-rank test. Where appropriate, a
stratified log-rank test and Cox proportional hazard model
will be used to explore the potential influences of baseline
HB and other specified covariates.
The secondary efficacy analysis will be based on the
Full Analysis Set (FAS) and the per protocol populations.
Significance level is set at an alpha of 0.05 and no adjust-
ment will be made for testing multiple secondary out-
comes. Some significant findings are expected to occur by
chance so undue consideration will not be given to any
particular significant difference. Moreover, interpretation
of the results will be based on patterns of differences and
in conjunction with the results of the primary analyses.
Cost analysis
Unit costing of distinct health care resources will be in
accordance with national guidelines [26]. Cost data will
be derived as the product sum of health care volume
data and their respective unit cost. Observed health util-
ities based on the EQ-5D health status profiles will be
linked to the lengths of the periods in between measure-
ments to derive QALYs. Incremental cost-effectiveness
and cost-utility analyses will be performed to calculate
the extra cost per additional ‘responder’ and the extra
costs per additional quality adjusted life year respectively.
Differences between groups will be assessed by calculating
95 % confidence intervals for the mean differences after
non-parametric bootstrapping, drawing at least 1,000
samples of the same size as the original sample separately
for each group and with replacement. A cost-effectiveness
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acceptability curve will be drawn to show the probability
of intravenous iron supplementation being cost- effective
at willingness-to-pay values up to €80,000 per QALY. Sin-
gle and multi-way sensitivity analyses will be performed to
study the robustness of these findings to plausible changes
in key unit costs and to alternative health utility scoring
algorithms [27]. With a time horizon of six months of
follow-up, no discounting of efficacy and cost data will be
applied to account for time preference.
Ethics and safety
This trial will be conducted according to the principles of
the declaration of Helsinki (Fortaleza, October 2013 ) and
in accordance with the Medical Research Involving Human
Subjects Act (WMO) and other European guidelines, regu-
lations and acts. Data management, monitoring and report-
ing of the study will be carried out in accordance with the
ICH GCP guidelines. The medical ethical committee of the
Academic Medical Centre, Amsterdam, the Netherlands,
has approved the study protocol (NL50013.018.14). As this
trial concerns the effectiveness of a medication a Data
Safety Monitoring Board (DSMB) will be assigned. The
DSMB will guard the safety of the included patients, give
advice on continuation of the study upon superiority of one
of the types of treatment, and will guard the methodological
quality of the study.
Discussion
This is the first randomized controlled trial to determine
the efficacy of preoperative iron supplementation in exclu-
sively anaemic patients with a colorectal carcinoma. In
current literature there are two randomized trials on pre-
operative iron supplementation for colorectal carcinoma
patients [20, 21]. Both included non-anaemic patients, were
small sized and used a fixed dosage of iron supplementation
[20]. As iron-therapy is unlikely to be effective when the pa-
tient has no deficiency this is a huge confounder in both
studies. Apart from these two randomized controlled trials
there are four cohort studies addressing preoperative iron
supplementation in patients undergoing surgery for colo-
rectal carcinoma [22, 28–30]. These four cohort series all
focussed mainly on perioperative blood transfusion rate.
Currently, in centralized centres the blood transfusion rate
after colorectal surgery is around 4 % [1]. This low blood
transfusion rate adds to the debate whether postoperative
transfusion is the most important clinical endpoint asses-
sing patients with anaemia.
It is well-known that anaemia is associated with impaired
physical performance and lower quality of life [5]. In a
retrospective cohort study of 227425 patients undergoing
non-cardiac surgery Musallam et al. [13] showed that
anaemia is associated with a higher postoperative morbid-
ity. A reduction in morbidity was seen in the non-anaemic
patients compared to anaemic patients from 28 % to 5 % in
non-anaemic patients. A reduction in postoperative mor-
bidity was also seen even in mild to moderate anaemic pa-
tients, compared to more severe anaemic patients. This
strengthens our hypothesis that more effective treatment of
anaemia improves the morbidity after surgery.
In current practice, the period between diagnosis and
surgery is approximately two to three weeks. This provides
a window of opportunity for treatment with iron supple-
mentation, as it takes time to increase the Hb-level with
iron therapy. Blood transfusions or erythropoietin stimu-
lating agents (ESA) are both successful in the treatment of
anaemia, but as these modalities significantly increase the
risk of recurrence and even mortality, they should be
given with restraint [31]. Both intravenous and oral ther-
apy are currently used and accepted as treatment of iron
deficiency anaemia. However, a study directly comparing
the effectiveness of both treatment options and simultan-
eously assessing the correlation with postoperative out-
come has never been performed. Therefore the primary
aim of this trial is to provide evidence on the safest and
most effective treatment option of anaemia in the limited
time period of the preoperative setting.
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